Introduction
Highly pathogenic avian influenza virus (HPAIV) can cause devastating losses in poultry. In several developing countries where small-scale, so-called 'sector four' or backyard poultry production is a significant source of food for the population, continuing HPAIV outbreaks may even lead to protein deprivation and malnutrition (2, 23) . In addition, several HPAI viruses (HPAIV) exhibit a zooanthroponotic potential and may cause fatal infections in humans (5) . All of these attributes particularly apply to HPAIV H5N1 of Asian origin. This virus, whose precursor surfaced in 1996 in the Chinese province Guangdong, spread over large parts of Asia and Europe and, in 2005, also reached the African continent (6) . In several Southeast Asian countries, as well as in parts of Africa and the Middle East, representatives of different lineages of this virus have established endemic infections with year-round viral activity detectable in poultry (11) .
There are several ways in which highly pathogenic infectious agents can establish endemicity. The clinical picture of an infection with HPAIV depends, among other factors, on the bird species affected (1) . In gallinaceous poultry, after a short time of incubation, a severely depressed general condition becomes apparent, and the birds die rapidly within days. In domestic waterfowl, however, substantial differences in clinical characteristics following an HPAIV infection have been noticed. This has been analysed in greater detail for HPAIV H5N1 of Asian origin (21, 29, 30) . Factors influencing the clinical course relate to species, age of animals and the virus strain (19, 18) . Introduction and subsequent spread of HPAIV H5N1 in duck flocks may, therefore, be clinically silent, as observed in live bird markets in Southeast Asia, where HPAIV H5N1 can be isolated year-round, mainly from clinically inconspicuous domestic water fowl, particularly ducks (11, 26) . Recent strains isolated from such outbreaks induce no clinical symptoms in ducks, but remain highly pathogenic for chickens and turkeys. Thus, during syndrome surveillance, infection will only be detected after spread into highly susceptible gallinaceous species (11) . This situation is not necessarily confined to backyard and rice-paddy rearing systems: industrial duck holdings with high biosecurity standards may also be affected, as demonstrated by clinically silent infections in two German holdings of fattening ducks in 2007 (12) . Furthermore, silently infected ducks living in close contact with humans increase the risk that HPAIV will cross the species barrier (17) . Human contacts with HPAIV are also conceivable via food products from silently infected ducks.
Therefore, measures to prevent, control or eradicate outbreaks of these viruses form an integral part of legislation worldwide (4, 22) . Prevention is principally based on biosecurity to prohibit virus incursion into Rev. sci. tech. Off. int. Epiz., 28 (1) 276 poultry holdings. However, the level of success depends on the structure of the poultry industry and on HPAIV epidemiology. Biosecurity measures are easier to implement in regions with a high percentage of wellcontrolled industrial poultry holdings. Sector four holdings, spatially highly clustered and inhomogeneous concerning age and species of poultry, pose a more severe problem in this respect.
Vaccination against HPAIV can increase barriers against an incursion of HPAIV. Successful vaccination is determined by:
-absence of symptoms after infection -an increased ability of vaccinees to resist infection -an effective reduction of virus shedding after infection.
Transmission of field virus will be interrupted when the reproduction factor R 0 drops below 1, thus ensuring eradication of the virus (32) . However, in a modelling approach, Savill et al. (24) demonstrated that even 90% vaccination coverage with currently available vaccines does not prevent clinically 'silent' field virus infections and further virus spread. A field vaccination study of chickens in Hong Kong resulted in 81.7% successfully vaccinated animals (7) . Today, in the European Union (EU), three inactivated oil emulsion vaccines are licensed and commercially available. Two of them are specific for subtype H5 (8) . Inactivated vaccines have to be administered individually via injection, causing significant logistical challenges. While it has been experimentally shown that R 0 can drop below 1 by using these vaccines (3, 31, 32) , it remains to be elucidated whether these results, obtained in a laboratory setting with very limited numbers of animals, can be extrapolated to conditions in commercial poultry production. Besides questions about the protective efficacy of the available vaccine in a field situation, there are also apprehensions that widespread and sustained, but uncontrolled, vaccination may facilitate the development by antigenic drift of variants which escape immunity induced by the vaccines (16, 26) .
This study evaluated the time and labour required for the vaccination of geese and duck flocks against HPAIV H5 under commercial conditions. Vaccine efficacy was investigated by the induction of antibodies, and by challenge experiments. The authors show that vaccinated, commercially reared geese parents are protected from disease but still can be infected and shed HPAIV H5N1 albeit at reduced levels and for shorter periods compared to non-vaccinated controls. Pekin ducks in this study proved to be clinically resistant against challenge virus infection and shed only very little virus, if any at all.
Material and methods

Study design and supervision of flocks
Two commercial, professionally reared free-range flocks were selected: one of goose parents (n = 1,200) and one of fattening Pekin ducks (n = 1,500). The holdings were operated under fully commercial conditions in Northwestern Germany; however, neither products nor animals from these flocks were allowed to be marketed during the trial. 
Vaccine and immunisation schemes
An inactivated and adjuvanted vaccine based on low pathogenic avian influenza virus (LPAIV) strain A/duck/Potsdam/1402/86 (H5N2) was used to immunise a subpopulation of the flocks. A total of 800 of 1,200 geese, and 1,000 of 1,500 ducks were vaccinated according to the manufacturer' s protocols (1.0 ml vaccine per animal). Primary AIV H5 vaccination of geese was performed at 17 weeks of age (Fig. 1a, squares) . Ducks received the primary AIV H5 vaccination at seven weeks of age (Fig. 1b The geese were vaccinated (□) at the age of 17 weeks (V1), 21 weeks (V2), 48 weeks (V3) and 77 weeks (V4). Sampling (○, swabs and blood) was done at week 17 (S1), 21 (S2), 25 (S3), 47 (S4), 50 (S5), 76 (S6) and 81 (S7). Challenge experiments (∆) were conducted in week 21 (C1), 25 (C2), 47 (C3) and 77 (C4) The ducks were vaccinated (□) at the age of 7 weeks (V1) and 11 weeks (V2). Sampling (○, swabs and blood) was done in week 7 (S1), 10 (S2), 14 (S3) and 25 (S4). Challenge experiments (∆) were conducted in week 10 (C1), 14 salmonellosis were carried out twice before the laying period in geese, and Pasteurella anatipestifer vaccine, based on a strain isolated from this herd, was applied at 12 days of age in ducks. All vaccines were given by intramuscular injection. The second AIV H5 vaccination ('booster') was performed four weeks after primary vaccination. The geese were revaccinated twice, after six and 12 months, following the booster vaccination. Avian influenza virusvaccinated animals were identified by a coloured plastic foot-ring imprinted 'AIV'. 
Flock sampling schedules
Challenge experiments
Vaccine efficacy as defined by protection against disease, infection, and excretion of HPAIV, was evaluated by challenge experiments using HPAIV A/Cygnus cygnus/Germany/R65/06 (H5N1). This strain had been isolated from a naturally infected whooper swan dying from the infection in Germany in spring 2006 (34) . At the time points (C) indicated by triangles in Figures 1a and 1b , eight vaccinated and eight non-vaccinated birds were withdrawn from each of the flocks and transported to the high containment facilities of the Friedrich-LoefflerInstitut, Insel Riems, Germany. Ducks and geese were transported separately and had no other contact. For challenge infection, each vaccinated animal was inoculated by the oculo-oronasal route with 10 6 50% egg infective dose (EID 50 ) of HPAIV H5N1 diluted in cell culture medium containing 10% foetal calf serum. Three nonvaccinated animals were inoculated with the same amount as controls. An aliquot of each inoculum was re-titrated to ensure proper dosage of the challenge virus. After 24 h, five non-vaccinated birds were added to the respective groups to check for contact infection. For the last challenge experiment (geese: C4), vaccinated birds were added instead. Animals were observed for ten days and clinical symptoms were recorded. Oropharyngeal and cloacal swabs were taken at days one, two, three, four, seven, nine and ten post inoculation (PI). Animals that died or had to be euthanised in a moribund state were referred for pathological investigations. Blood samples were obtained from all animals before inoculation and from all surviving birds at the end of the observation period.
Virus detection by real-time reverse transcriptase polymerase chain reaction
Ribonucleic acid was isolated from swabs either manually using the Viral RNA kit of Qiagen (Hilden, Germany) or automatically with the Nucleospin 96 Virus Extraction Kit (Macherey & Nagel, Germany) on a Tecan Freedom Evo ® pipetting platform. One-step real-time reverse transcriptase polymerase chain reaction (rRT-PCR) for detection of an M-gene fragment (27, modified by 33) was carried out for swabs taken from the flocks. Five of these swabs were pooled for rRT-PCR analysis. Single swabs from positive pools were re-tested. Single positive swab samples were then tested by rRT-PCR for presence of H5-(25) and H7-genome fragments (27, modified by 33).
Swabs taken from birds during the challenge experiments were processed individually and examined by the H5-specific rRT-PCR only.
Molecular characterisation of non-H5/H7 avian influenza virus
Swab samples taken from the flocks which apparently harboured AIV RNA were further subjected to conventional reverse transcriptase polymerase chain reaction (RT-PCR) for an HA2-gene fragment (21) . Resulting amplification products were sequenced directly as described (28) . Assembled sequences were used for BLASTN2 database searches to identify the corresponding haemagluttinin (HA) subtype. The neuraminidase (NA) subtype was identified following the method of Fereidouni et al. (10) . These samples were also subjected to virus isolation.
Virus isolation in embryonated chicken eggs
Swabs were processed and supernatants inoculated into embryonated chicken eggs according to the EU diagnostic manual (9) . Two passages each of five days were carried out after inoculation of nine-to 11 day old embryonated eggs. Detection of haemagglutinating activity in amnio-allantoic fluids prompted further molecular investigation, as described above, to verify the presence of AIV.
Virus titration in cell culture
Serial tenfold dilutions were made from swab fluids or challenge virus inocula in cell culture medium containing 10% foetal calf-serum, and used to infect MV1Lu cells (ATCC CCL 64) during seeding into microtitre plates (100 µl per well; four replicas per dilution). MV1Lu cultures were grown in Dulbecco' s modified Eagle' s medium containing 10% foetal calf serum. The cultures were incubated at 37°C in 5% CO 2 for three days, after which infected cells were identified by an immune peroxidase monolayer assay (IPMA) targeting the viral nucleocapsid protein (NP). To this end, cell monolayers in microtitre plates were fixed using a 1/1 (vol/vol) mixture of methanol and acetone at -20°C after removing the medium and rinsing the monolayer once with phosphatebuffered saline (PBS). Fixed cells were rehydrated with PBS, and then overlaid with appropriately diluted anti-NP monoclonal antibody (ATCC HB 65) for one hour at room temperature. After two washes with PBS containing 0.05% (vol/vol) Tween 20, the cells were overlaid with anti-Mouse IgG peroxidase conjugate (Sigma, Saint Louis, Missouri, United States of America) for 1 h. Following another wash, cells were stained with 3-aminoethylcarbazole and H 2 O 2 . Coarse intracellular granular reddish precipitates were used to identify antigen-positive cells by light microscopy at a magnification of 200×. Infectivity titres were estimated according to Karber (13) .
Detection of avian influenza virus nucleocapsid protein-specific antibodies by competitive enzyme-linked immunosorbent assay
Heparinised blood samples were screened for AIV-specific antibodies using the AI A blocking enzyme-linked immunosorbent assay (ELISA) (Institut Pourquier, Montpellier, France), or the ID Screen ® Influenza A NP Antibody Competition ELISA (ID VET, Montpellier, France). These tests enable a qualitative detection of antibodies directed against the influenza A virus NP protein of all subtypes. Both assays appeared to have comparable performance according to the authors' validation data (not shown) and were therefore used interchangeably. The instructions of the suppliers were followed exactly. Positive samples were further tested for subtype-specific reactivity by haemagglutination inhibition (HI). Depending on the small sample size of different groups, Fisher' s exact test was used to verify differences in the distributions of data measured. Survival analysis was performed by the log rank test. The sign-test was performed to compare connected samples of values on an ordinal scale, e.g. titres. For result interpretation a strictly defined significance level at p-value 0.05 was used. Multiple tests on the same data according to the critical significance levels were not corrected.
Detection of avian influenza virus subtype-specific antibodies by haemagglutination inhibition
Statistical analysis
Results
Monitoring trial flocks reveals undisturbed general health but suboptimal production parameters
During the whole study period the health status of the geese and duck flocks was very good. Gross-pathological investigations of dead or randomly selected diseased birds revealed that these cases were largely the result of injuries accidentally caused by manipulation during sampling and vaccination (particularly manipulation to obtain blood samples). After blood sampling, a few (4 to 6) birds per flock died, due to uncontrolled bleeding from the injection site, or had to be euthanised because of broken wings or leg injuries incurred when the birds panicked during capture.
Geese
During the first and second laying periods, 82 and 61 animals, respectively, died or were selected for pathological examination for various reasons. These figures include 13 losses by predators (foxes). A more frequent cause of loss was oviduct-peritonitis in laying geese, probably also provoked or aggravated by capture. Sixtyfour geese were removed for challenge infections. The birds produced on average 32 eggs each. This value is at the lower range of normal production. It could well be that frequent handling for sampling and vaccination had a negative influence on egg production. Likewise, forage consumption of 3.37 kg/egg and 1.97 kg/egg, in the first and second laying periods, respectively, is not representative, due to extra rations used for baiting the animals during manipulations.
Ducks
In the duck flock 52 birds died during the 126 day observation period due to accidents during handling and a further 48 birds were used for challenge experiments. The average animal weight at the end of the fattening period was 3,680 g (a gain of 880 g). Usually, a fattening period for ducks does not exceed 49 days; however, in this experiment other conditions prevailed according to the objectives of the study. Consequently, no values for forage consumption are indicated.
Avian influenza virus vaccination by injection was logistically demanding but prompted no significant vaccine-induced side-effects in the birds
No adverse reactions during and after application of the vaccine were observed in geese or ducks. During capture and manipulation of the animals for vaccination considerable care had to be taken to prevent injuries, overheating and suffocation of the birds, particularly in layers (see above). Precautionary measures demanded up to two additional technical assistants than usually considered for vaccination of gallinaceous poultry. For vaccination of 800 geese within three hours five persons were required. This included additional work to separate vaccinated geese from non-vaccinated controls during revaccination runs. Two thirds of the ducks (1,000 animals) were vaccinated within three hours by a total of five people.
Special care had to be taken when marking vaccinated birds by ringing. Open rings have proven inapt, so since only closed rings can be used there is only a short time span during which the rings can be fitted onto the leg without immediate loss of the ring. It took three people 5 hours to ring 800 geese, and four people 4 hours to ring 1,000 ducks.
Avian influenza virus-specific antibody titres in flocks decreased with temporal distance from revaccination
All blood samples taken prior to vaccination tested negative for AIV NP-specific antibodies. Considering the performance of the ELISAs used, the AIV seroprevalence in the herds prior to vaccination was estimated to be <4.87%, and the herds were classified to be seronegative and fully susceptible for AIV infections.
Geese
Only one AIV NP and H5 seropositive sample was detected throughout the observation period (n = 420 samples) among the non-vaccinated birds. Most likely this sample was from a vaccinated bird which had lost its foot ring. Generally, 89.54% ELISA-positive samples turned out to be positive (≥ 4 log 2 ) in HI-test. In vaccinated geese, there was a gradual increase of H5-specific mean titres over the course of the observation period (Fig. 2a) . After the second vaccination (S3), 92% of the vaccinated geese showed H5 vaccine-specific antibody titres ≥ 5 log 2 . In the observation period that followed titres declined with temporal distance from the last vaccination to below 4 log 2 and were boosted after each revaccination (Fig. 2a) . Titres against the challenge virus were 3 to 7 log 2 steps lower.
Ducks
Development of AIV H5-specific antibodies in vaccinated ducks (Fig. 2b ) took a similar course and all tested birds showed AIV-specific antibody titres ≥5 log 2 after booster vaccination (S3), which only marginally decreased after 11 weeks (S4). Surprisingly, and in contrast to the geese flock, AIV NP-specific antibodies were also detected in non-vaccinated ducks (Fig. 2b ) from week 10 onwards (S2). According to virological investigations (see below), this was most likely due to a natural infection with an AIV field isolate of subtype H10. Using a recent H10N7 isolate originating from wild birds in Germany, development and rapid decline of H10-specific mean HI antibody-titres was evident in non-vaccinated ducks (Fig. 2b, triangles) . Also, some vaccinated ducks developed H10-specific antibodies, albeit at lower frequency and titres compared to non-vaccinated animals.
Virological monitoring revealed a natural avian influenza virus infection in the free-range duck herd but not in the geese flock
Geese By generic AIV rRT-PCR specific for an M gene fragment no evidence for naturally occurring influenza A virus infections was obtained during the study period, in either the vaccinated or non-vaccinated subpopulation.
Ducks
Prior to vaccination (S1) all swabs tested negative for AIV RNA. However, at three weeks after the first vaccination (S2) Immunologically naïve geese and ducks were susceptible to challenge virus infection but only geese developed significant central nervous symptoms and mortality
Geese
In the first two challenge experiments (C1, C2), three nonvaccinated animals were each inoculated with 10 6 EID 50 of HPAIV H5N1 as controls. All of these animals fell sick, and five out of six died. Clinically, central nervous symptoms such as altered behaviour, phases of circular motion and severe torticollis were observed from 4 days post inoculation (dpi). The geese died or were euthanised in moribund status between dpi 6 and 10. Pathological alterations found in dead animals were non-specific, consisting primarily of mucosal haemorrhages in proventriculus or pancreatitis. For animal welfare reasons no non-vaccinated controls were used in challenge experiments C3 and C4 since the pathogenicity of the challenge strain for susceptible geese had been demonstrated adequately.
Ducks
During each of the three challenge experiments three nonvaccinated ducks were inoculated with 10 6 EID 50 of HPAIV H5N1 as controls. All of these animals had low titres of H10-specific antibodies (mean titre C1: 4 log 2 ; C2: 4 log 2 ; C3: 2.7 log 2 ). None of these ducks developed any clinical signs.
Absence of clinical signs in challenged vaccinated geese and ducks
With the single exception of one animal which died during challenge at C4, vaccinated geese fully resisted an inoculation of 10 6 EID 50 of HPAIV H5N1 with respect to clinical symptoms, even after a single vaccination (Fig. 3) . The one dead animal shed virus up to a Ct-value of 25 and showed a mild rhinitis and pancreatitis. As expected, vaccinated animals did not show clinical symptoms upon exposure to 10 6 EID 50 of HPAIV H5N1 (not shown).
Like the non-vaccinated ducks, the vaccinated ducks displayed no clinical signs.
Vaccinated geese and ducks transmitted challenge virus to non-vaccinated and vaccinated sentinels, although reduced challenge virus excretion in level and duration was evident
Geese
During challenge trial C1, three weeks after the first vaccination, all five non-vaccinated in-contact animals died on dpi 10 due to HPAIV H5N1 infection, while all vaccinated animals survived without developing clinical symptoms. At C2, three weeks after the second vaccination, two of five non-vaccinated in-contact animals died on dpi 10. At C3, one of five non-vaccinated animals died on dpi 8. C4 was conducted six months after the first revaccination. In contrast to previous challenge experiments, the in-contact birds had also been vaccinated. While none of the vaccinated contact animals died, one of eight vaccinated and inoculated geese fell severely ill and died due to challenge virus infection.
Intermittent virus shedding started at dpi 1 in inoculated geese (Table I) . Until dpi 10, episodic excretion from the oropharynx and/or the cloaca was evident for vaccinated geese in all challenge experiments. Non-vaccinated in- infectious HPAIV H5N1 detectable in cell culture with a TCID 50 of 10 2.1 to 10 3.6 per ml. Two of five vaccinated contact birds seroconverted against the challenge virus, indicating that they had become infected.
Ducks
In Table II the results of the duck challenge trials are summarised. Only low loads (Ct-values >30) of H5-specific AIV RNA were detected in a few cases scattered across the observation period. The HPAIV H5N1 was reisolated from only two cases: a vaccinated duck (C1, dpi 1), and one non-vaccinated in-contact animal (C3, dpi 4).
Vaccinated birds revealed increased avian influenzaspecific haemagglutination inhibition titres after challenge experiments
As shown in Figure 4 , in each challenge experiment with HPAIV H5N1 a booster effect on the vaccine-induced H5-specific antibody titres (>4 log 2 steps) was evident in the vaccinated birds. The increase in antibody titre was most significant for antibodies against the challenge virus, but an increase against vaccine antigen was also evident in most cases.
Discussion
An efficacy assessment of an inactivated adjuvanted vaccine against HPAIV H5N1 infection in commercially reared flocks of geese parents and fattening ducks was carried out. Feasibility of application, protection against disease, and protection against infection with, and excretion of, HPAIV field virus were investigated.
Feasibility of vaccine application
Intramuscular application of the vaccine posed no particular problems in 16-week-old geese or in 7-week-old fattening ducks. About 200 birds were injected per hour by one person with the help of three or four assistants. This included time required to identify the bird' s vaccination status by reading the leg ring. It should be mentioned that remnants of oil from the absorbed vaccine were detected in breast muscles of fattening ducks for up to 50 days after vaccination. This may cause problems in marketing meat products from these animals; a subcutaneous route of application would be preferable. Combined swabs 0/1 DPI: days post inoculation n/m: number of swabs tested positive in cell culture / total number of real-time reverse transcription polymerase chain reaction positive swabs (for the purposes of the experiment no distinction was made between oropharyngeal and cloacal swabs) VI: average virus isolation and titration in MV1Lu-cells
Protection against disease
A considerable host-and virus-strain-related variability in the clinical outcome of HPAIV infections in waterfowl has been documented (18, 19, 21, 30) . The challenge strain chosen for this study originated from an outbreak in wild birds in Northern Germany in 2006. It exhibited an intravenous pathogenicity index of 2.97 in chickens (34) and caused significant mortality, though not a 100%, in susceptible adult geese within ten days. This strain, like others, shows an age-dependent pathogenicity in Pekin ducks, causing 100% mortality in four week-old animals (Rudolf et al., in preparation), but did not induce any detectable clinical signs in adult Pekin ducks. Moreover, virus replication seemed to be limited in adult ducks in line with the restricted virus excretion. Nevertheless, successful challenge virus infection of all animals was indicated by seroconversion at dpi 10 ( Fig. 4) . Thus, concerning protection from disease, no effect of vaccination could be assessed.
A possible co-protective role of heterosubtypic immunity induced by the accidental, natural infection with an AIV of subtype H10 in the free ranging duck flock is unclear. Even if, at C3, H10-specific antibodies were no longer detectable, cellular immunological memory functions may have been still active.
In contrast, the protective effects of the vaccination of geese were statistically verified (Table III) : vaccination protected successfully against illness and death. (In C1 protection could not be formally verified, as one out of three nonvaccinated control animals survived as well.) A KaplanMeier Curve (Fig. 3) shows that there is a 100% probability that vaccinated animals will stay healthy, only in C4 did one vaccinated animal die. Analysis by Fisher' s exact test shows significant (p<0.05) differences between healthy and diseased/dead animals in vaccinated and nonvaccinated groups.
Protection against infection with, and excretion of, highly pathogenic avian influenza field virus
One of the gravest concerns about vaccination against HPAIV is the risk of clinically silent HPAIV infections under immune coverage. According to mathematical modelling (24) very high levels of population immunity are required to completely suppress both infection and spread. However, there are no accurate data available on immunisation rates of different poultry species under field conditions, since all data were obtained from trials run under experimental conditions. The HI-specific antibody titres correlate with clinical protection and, in chickens, an HI-titre of ≥ 5 log 2 was associated with good protection (15) . However, a similar correlation has not been made in other avian species.
In the two waterfowl species examined here the development of specific humoral immunity was evaluated by NP-specific antibody ELISA and by strain-specific HI.
In line with previous experiences, ducks and geese in our study reached, on average, lower antibody titres compared with chickens. In addition, in geese, these titres declined more rapidly (14) , so that only 40% of vaccinees had titres of 5 log 2 six months after the basic immunisation. Therefore, bi-annual revaccinations of geese were required to keep the average HI titre against the homologous (vaccine virus) antigen at ≥5 log 2 in at least 90% of vaccinees. In contrast, basic immunisation of ducks was sufficient to maintain this level during the observation period. Antibody titres against the heterologous HPAIV H5N1 challenge virus were significantly lower, which was expected due to the comparatively large differences between the two viruses (homology of HA sequences 92%).
However, in the author' s study no vaccinated geese showed overt signs of disease upon challenge, not even animals with an average HI titre of 2.4 log 2 (±1.4) against the homologous vaccine virus antigen at C3, which is considerably lower than anticipated for solid clinical protection in chickens (15) . Similar findings were seen in the other challenge experiments. The one goose which died in C4 had no detectable antibodies against the vaccine antigen prior to challenge. Interestingly, in the same experiment, two other animals without detectable antibodies survived the challenge infection. Therefore, the predictive value of specific HI antibody titres as an indicator of the protective efficacy of vaccination in geese seems to be questionable. This may also point towards a substantial contribution to protection of the cellular immune response.
In order to evaluate protection from infection with, and excretion of, HPAIV, vaccinated birds were challenged with a recent H5N1 HPAIV of Asian origin. In addition to evaluation of challenge virus excretion by molecular and virological methods, non-vaccinated in-contact birds (sentinels) were chosen to closely mimic a field situation in a flock with a heterogenous H5-specific immune status. This approach formally interferes with a calculation of R 0 levels (since this would require animals of similar immune status [32] ), but it was chosen since it more likely resembles a realistic situation in the field. However, for the final challenge experiment (C4) vaccinated in-contact geese were used.
In the geese experiments, challenged vaccinated birds became infected and excreted challenge virus albeit at lower titres and intermittently compared to non-vaccinated control geese which received the same inoculation dose. Non-vaccinated in-contact geese acquired the infection after challenge virus transmission from vaccinated birds and developed clinical disease in experiments C1 and C2. Only one of five non-vaccinated in-contact geese succumbed to the infection in the third trial (C3), although all in-contact birds became infected (TCID 50 ranged between 10 1.6 and 10 3.1 ). The authors were not able to clearly demonstrate transmission of challenge virus to vaccinated in-contact animals (C4), as only one out of five contact animals revealed an rRT-PCR positive swab and on only one occasion. Nevertheless, seroconversion against the challenge virus indicates infection of at least two of the vaccinated in-contact geese of C4 (Table IV) .
Successful re-isolation of virus from comparatively few of the PCR-positive animals (Tables I and II) indicates that the cell system used is not as sensitive as live sentinel birds. Thus, despite the inability to re-isolate challenge virus, transmission of virus from vaccinated animals to nonvaccinated sentinels did occur.
For reasons detailed above, no proper assessment of the protective efficacy of the vaccination was possible for the ducks. We only detected low levels of virus shedding, and virus re-isolation was only possible in isolated cases even in non-vaccinated animals. Nevertheless, we found significantly higher numbers of rRT-PCR positive swabs in the non-vaccinated animals than in the vaccinated birds (7 out of 384 swabs from vaccinated ducks versus 28 out of 144 swabs from non-vaccinated ducks; p< 0.0001, Fisher' s exact test). This indicates that vaccination led to a detectable reduction of virus shedding, even if none of the Resumen Los virus de la influenza aviar altamente patógena (virus IAAP) pueden causar pérdidas devastadoras para el sector avícola. Además, varios de ellos presentan potencial zooantroponótico y pueden provocar infecciones mortales en el ser humano. Estas características se aplican especialmente a la cepa H5N1 del virus IAAP, de origen asiático. Debido a la ausencia de síntomas clínicos ostensibles, la penetración y subsiguiente propagación de dicha cepa en aves acuáticas domésticas (en especial el pato) pueden pasar desapercibidas, lo que incrementa el riesgo de transmisión a otras especies muy vulnerables de gallináceas o mamíferos, comprendido el ser humano. Las personas también pueden resultar infectadas por la cepa H5N1 al ingerir alimentos procedentes de patos que portaban una infección silente al ser sacrificados. La vacunación contra el virus puede conferir protección contra una incursión vírica, por cuanto, al menos en condiciones experimentales, hace descender el factor de reproducción (factor R 0 ) por debajo de 1, lo que garantiza la eliminación del virus. Los autores describen un estudio encaminado a determinar si es posible obtener resultados similares en condiciones naturales tras administrar una vacuna patentada (a base de virus H5N2 inactivados con adyuvante) a bandadas industriales de ocas reproductoras y patos de engorde criadas en libertad. La vacunación de esas bandadas de ocas y patos fue más larga y laboriosa de lo previsto, sobre todo por la necesidad de clasificar a los animales según sus anillas identificativas. No se observó ningún efecto adverso relacionado directamente con la vacunación. Por lo que respecta a la serología, se indujo una respuesta homogénea de anticuerpos específicos de las cepas H5. Los títulos de anticuerpos variaban según el tiempo transcurrido desde la última administración de vacuna. Las ocas reproductoras quedaron clínicamente protegidas contra la infección experimental por virus IAAP A/Cygnus cygnus/Germany/R65/06 (H5N1), pero aún podían resultar infectadas por la cepa vírica H5N1 y a su vez transmitirla, aunque en niveles menores y por períodos más cortos que los animales testigo no vacunados. Los patos de Pekín, en cambio, resultaron ser clínicamente resistentes a la inoculación experimental y excretar muy pocos virus.
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